These data that decrease Mcl-1 expression and inhibits cell viability by inhibition of NF-κB pathway support the use of selective NF-κB inhibitors in the treatment of Mcl-1-overexpressing human ESCC. Here, NFKB1 is linked to esophageal squamous cell carcinoma.